Metagenomi Therapeutics, Inc. (MGX)
NASDAQ: MGX · Real-Time Price · USD
1.390
+0.020 (1.46%)
Mar 25, 2026, 4:00 PM EDT - Market closed

Metagenomi Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2022
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
5261135---
Market Cap Growth
-30.83%-54.88%----
Enterprise Value
-67.85-65.22-73.04000
Last Close Price
1.391.623.61---
PE Ratio
--0.69-1.53---
PS Ratio
2.072.422.58---
PB Ratio
0.330.380.58---
P/TBV Ratio
0.330.380.51---
P/FCF Ratio
--0.68-1.20---
P/OCF Ratio
--0.69-1.24---
EV/Sales Ratio
--2.59-1.40---
EV/EBITDA Ratio
-0.720.87---
EV/EBIT Ratio
-0.680.82---
EV/FCF Ratio
-0.730.65---
Debt / Equity Ratio
0.220.220.170.210.061.10
Debt / EBITDA Ratio
-0.45-0.45-0.55-0.65-0.43-2.08
Debt / FCF Ratio
-0.45-0.45-0.41-0.481.182.29
Net Debt / Equity Ratio
-0.76-0.76-0.861.644.621.82
Net Debt / EBITDA Ratio
1.331.332.433.008.012.51
Net Debt / FCF Ratio
1.341.341.812.20-21.82-2.77
Asset Turnover
0.090.090.150.110.060.00
Quick Ratio
7.027.026.693.977.494.30
Current Ratio
7.227.226.914.047.564.33
Return on Equity (ROE)
-44.67%-44.67%-34.69%-28.04%-27.62%-48.79%
Return on Assets (ROA)
-35.17%-35.17%-24.09%-22.83%-17.05%-16.87%
Return on Invested Capital (ROIC)
-160.68%-160.68%-112.41%-145.88%-134.56%-82.71%
Return on Capital Employed (ROCE)
-39.56%-39.56%-30.48%-23.72%-18.49%-20.50%
Earnings Yield
-168.03%-145.68%-65.37%---
FCF Yield
-171.09%-146.80%-83.05%---
Buyback Yield / Dilution
-0.33%-0.33%-62.19%---
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q